Aquestive Therapeutics, Inc. Common Stock vs. Eli Lilly & Co.
Aquestive Therapeutics, Inc. Common Stock and Eli Lilly & Co. are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| AQST | LLY | |
|---|---|---|
| Market Cap | $584.88 million | $1.12 trillion |
| Revenue (TTM) | $54.09 million | $79.67 billion |
| Net Income (TTM) | $-78,227,000 | $26.71 billion |
LLY leads on 3 of 3 size & scale factors.
Valuation
| AQST | LLY | |
|---|---|---|
| P/E Ratio | — | 42.14 |
| Price / Book | -10.34 | 33.03 |
| Price / Sales | 10.81 | 14.05 |
AQST leads on 2 of 2 valuation factors.
Profitability
| AQST | LLY | |
|---|---|---|
| Net Margin | -144.63% | 33.53% |
| Return on Equity | 138.24% | 78.84% |
AQST and LLY split the profitability factors evenly.
Dividend
| AQST | LLY | |
|---|---|---|
| Dividend Yield | — | 0.55% |
| Payout Ratio | — | 23.23 |
AQST and LLY split the dividend factors evenly.
Risk & Sentiment
| AQST | LLY | |
|---|---|---|
| Short Interest | 0.00% | 1.29% |
AQST leads on 1 of 1 risk & sentiment factors.
Dig deeper: AQST overview, AQST financials, LLY overview, LLY financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.